Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.72), $0.01 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $0 versus the consensus estimate of $7.47 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.